Short answer
aTYR PHARMA INC (ATYR) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$18M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$18M
- +29.1% YoY · −77.1% QoQ
- EPS (diluted)
- −$15.82
- −5759.3% YoY · −14281.8% QoQ
Source: XBRL data from the aTYR PHARMA INC (ATYR) Q3 2026 10-Q on SEC EDGAR. USD.
aTYR PHARMA INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, down $190,000 YoY from license and collaboration agreement revenue
- R&D expenses $10.4M vs $22.1M YoY, down $11.7M
- Worst performer: efzofitimod expenses $1.5M vs $18.8M, down $17.2M
- Cash, equivalents, restricted cash and investments $50.3M; operating cash used $31.4M
- Near-term outlook: lower expenses after restructuring and strategic-partnership prioritization, with capital needs remaining beyond one year
Risk Factors
- Newly added regulatory risk: FDA viewed EFZO-FIT as failed, with the Proposed Phase 3 Study potentially insufficient for approval
- Most material operational change: CDMO received a March 2026 Form 483 and plans microbial-site relocation, threatening future manufacturing continuity
- Most impactful financial risk: $50.3 million available liquidity, with additional capital needed for later clinical development and commercialization
- Near-term execution risk: Proposed Phase 3 Study activities expected in fourth quarter 2026, but advancement depends on securing a strategic partner
- Workforce risk: August 2026 restructuring reduced total employees by approximately 60% to 20 full-time employees
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other aTYR PHARMA INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.